FDA Grants Fast Track Designation to Nipocalimab for Lupus

March 2026

By Max R. Wursta Fact checked by Shenaz Bagha

Key takeaways:

• Nipocalimab is a potentially steroid sparing, immunoselective treatment designed to block FcRn and target IgG antibodies.
• The drug showed positive results and steroid sparing potential in a phase 2 trial.

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release.

Perspective from David A. McLain, MD, MACR, FACP, FRCP

Nipocalimab (Imaavy, Johnson & Johnson) is an investigational immunoselective therapy that blocks FcRn and targets harmful IgG antibodies to reduce SLE disease activity, Johnson & Johnson said in the release.

“The fast-tracking of nipocalimab for the treatment of SLE represents an exciting potential advancement for our field,” Ashira D. Blazer, MD,assistant professor of medicine in the division of rheumatology at the University of Maryland, told Healio.

“Nipocalimab has a novel immunomodulatory mechanism of action,” she added. “This approach may offer a new way to address some of the persistent challenges we face in caring for patients with SLE.”

The fast-track designation comes after a 52-week, phase 2 study of 228 adult patients with SLE, in which nipocalimab demonstrated positive results and steroid-sparing potential. According to the release, the manufacturer has announced enrollment for a phase 3 study of adults with active SLE.

“We are entering a new era of targeted therapies for SLE, but there are still several important unmet needs,” Blazer said. “These include the significant disease heterogeneity, as well as incomplete treatment responses and continued reliance on glucocorticoids.”

In addition, Blazer said pregnancy-related complications such as neonatal heart block still remain a concern for patients with SLE.

“Overall, I’m encouraged by these advances and excited about what they may mean for the future of lupus care,” she told Healio.

CLICK HERE to read more